Şirket yükleniyor
Just reported
Q3 2026 results
From Emergent Biosolutions's results release of 2 Kasım 2026; its quarterly report has since been filed.
Revenue
Actual
$110M
-%52 y/y
-%53 q/qGuided
$120M
midpoint
Within guide-%8,3EPS, GAAP
Actual
-$0,64
Guided
—
No guide given
Operating income, GAAP
Actual
-$37,3M
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue$600M – $645M-%16 y/y Lowered -%5,7
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Emergent Biosolutions is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$33,9BA
NBIXNeurocrine Biosciences, Inc.$17,2BA+
ELANElanco Animal Health Incorporated$13,3BA
KNSAKiniksa Pharmaceuticals International, plc$8,2BA+
LQDALiquidia Corporation$5,2BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
BIIBBiogen Inc.28 Eki 2026BAGraded B, now A
Emergent Biosolutions Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
